Joint Clinical Trials Office
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemo
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
The WCM Advancing HIV Health through Epigenetic studies in Aging and Alzheimer's Disease (AHEAD) Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 11, 2023
Feasibility and Acceptability of a Mobile Cognitive Behavior Therapy App Targeting Depression and Anxiety in Middle Aged and Older Adults
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 11, 2023
Assessing the effect of abstinence period on semen analysis parameters
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 17, 2023
UA COVID-19 National Registry: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 23, 2023
Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors with DNA-Repair Defects
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 23, 2023
Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 23, 2023
A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 23, 2023